• 1
    Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 3217.
  • 2
    Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 166978.
  • 3
    Marchand M, van Baren N, Weynants P et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80: 21930.
  • 4
    Yamshchikov GV, Barnd DL, Eastham S et al. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 2001; 92: 70311.
  • 5
    Matsui M, Moots RJ, Warburton RJ et al. Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition. J Immunol 1995; 154: 108896.
  • 6
    Falo LD Jr, Colarusso LJ, Benacerraf B et al. Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules. Proc Natl Acad Sci USA 1992; 89: 834750.
  • 7
    Amoscato AA, Prenovitz DA, Lotze MT. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J Immunol 1998; 161: 402332.
  • 8
    Chen W, Yewdell JW, Levine RL et al. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J Exp Med 1999; 189: 175764.
  • 9
    Meadows L, Wang W, den Haan JM et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997; 6: 27381.
  • 10
    Nakatsura T, Yoshitake Y, Senju S et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306: 1625.
  • 11
    Shirakawa H, Suzuki H, Shimomura M et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009; 100: 14037.
  • 12
    Nakatsura T, Komori H, Kubo T et al. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004; 10: 863040.
  • 13
    Nakatsura T, Kageshita T, Ito S et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004; 10: 661221.
  • 14
    Motomura Y, Senju S, Nakatsura T et al. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res 2006; 66: 241422.
  • 15
    Komori H, Nakatsura T, Senju S et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12: 268997.
  • 16
    Motomura Y, Ikuta Y, Kuronuma T et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol 2008; 32: 98590.
  • 17
    Salgaller ML, Marincola FM, Cormier JN et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56: 474957.
  • 18
    So T, Hanagiri T, Chapiro J et al. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195–203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules. Cancer Immunol Immunother 2007; 56: 25969.
  • 19
    Sorensen RB, Junker N, Kirkin A et al. The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines. Cancer Immunol Immunother 2009; 58: 66575.
  • 20
    Rubio V, Stuge TB, Singh N et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003; 9: 137782.
  • 21
    Rosenberg SA, Restifo NP, Yang JC et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299308.
  • 22
    Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 52339.
  • 23
    Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 1269.
  • 24
    Cole DJ, Weil DP, Shilyansky J et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res 1995; 55: 74852.
  • 25
    Hughes MS, Yu YY, Dudley ME et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther 2005; 16: 45772.
  • 26
    Morgan RA, Dudley ME, Yu YY et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003; 171: 328795.